Irinotecan liposomes for first-line advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new type of chemotherapy (irinotecan liposomes) as a first treatment for metastatic colorectal cancer that has not been treated before. It focuses on patients with specific genetic changes (RAS or BRAF V600E mutation) or right-sided colon cancer, and looks at how well the drug works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- Your colorectal cancer has spread and cannot be removed by surgery, and you have not had any systemic therapy for this stage.
- Your tumor has a RAS or BRAF V600E mutation, or is located on the right side of the colon.
- You are in relatively good general health (ECOG 0 or 1) with normal blood and organ function.
- You have at least one measurable tumor that can be tracked by scans.
- You agree to use contraception if of childbearing potential.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new form of the chemotherapy drug irinotecan (inside tiny fat particles) as a maintenance treatment for people with metastatic colorectal cancer that has responded well to initial chemotherapy. It aims to keep the cancer from growing longer.
This trial tests a new drug combination for colorectal cancer that has spread to other parts of the body and did not respond to or could not tolerate standard first-line chemotherapy. The goal is to see if this new approach can help shrink the cancer and extend survival.
This trial tests a combination of immunotherapy (sintilimab), a targeted therapy (cetuximab), and chemotherapy as a first treatment for advanced colorectal cancer that hasn't spread or come back after earlier treatment. It's for people whose tumors have certain genetic markers (RAS/BRAF wild-type) and show signs of immune activity (PD-L1 or CD8+ TILs).
This trial tests a new chemotherapy drug called liposomal irinotecan as a second treatment for metastatic colorectal cancer (cancer that has spread beyond the colon or rectum). You would be eligible if your cancer progressed after your first chemotherapy treatment and you're in good enough health to receive more treatment.
This trial tests a new form of chemotherapy (liposomal irinotecan) combined with two standard drugs (5-FU and leucovorin) and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this combination shrinks tumors and helps people live longer.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.